BR0314629A - Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso - Google Patents

Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso

Info

Publication number
BR0314629A
BR0314629A BR0314629-4A BR0314629A BR0314629A BR 0314629 A BR0314629 A BR 0314629A BR 0314629 A BR0314629 A BR 0314629A BR 0314629 A BR0314629 A BR 0314629A
Authority
BR
Brazil
Prior art keywords
polypeptides
ariasi
perniciosus
methods
polynucleotides
Prior art date
Application number
BR0314629-4A
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Francis Milward
Jose M C Ribiero
Shaden Kamhawi
Yasmine Belkaid
Laurent Fischer
Jesus G Valenzuela
Original Assignee
Us Gov Health & Human Serv
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Merial Ltd filed Critical Us Gov Health & Human Serv
Publication of BR0314629A publication Critical patent/BR0314629A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0003Invertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"POLIPEPTìDEOS DE P. ARIASI, POLIPEPTìDEOS DE P. PERNICIOSUS E MéTODOS DE USO". São descritos polipeptídeos P. ariasi e P. perniciosus salivar substancialmente purificados, e polinucleotídeos codificando estes polipeptídeos. Vetores e células hospedeiras incluindo os polinucleotídeos P. ariasi e P. perniciosus são também descritos. Em uma modalidade, um método é descrito para induzir uma resposta imune à saliva de mosquito-pólvora. Em outras modalidades, são descritos métodos para tratar ou prevenir Leishmaniasis.
BR0314629-4A 2002-09-19 2003-09-18 Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso BR0314629A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41232702P 2002-09-19 2002-09-19
US42585202P 2002-11-12 2002-11-12
PCT/US2003/029833 WO2004027041A2 (en) 2002-09-19 2003-09-18 P. ariasi polypeptides, p. perniciosus polypeptides and methods of use

Publications (1)

Publication Number Publication Date
BR0314629A true BR0314629A (pt) 2005-08-02

Family

ID=32033599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314629-4A BR0314629A (pt) 2002-09-19 2003-09-18 Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso

Country Status (7)

Country Link
US (2) US7741437B2 (pt)
EP (2) EP2158917A1 (pt)
JP (2) JP2006516883A (pt)
AU (1) AU2003275127A1 (pt)
BR (1) BR0314629A (pt)
MX (1) MXPA05003049A (pt)
WO (1) WO2004027041A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU2003287267A1 (en) 2002-10-29 2004-05-25 Centro De Pesquisas Goncalo Moniz Lutzomyia longipalpis polypeptides and methods of use
US9101557B2 (en) * 2011-04-13 2015-08-11 Auburn University Combination of protein forms for hornfly vaccination

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
ATE143052T1 (de) 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5397772A (en) * 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5585103A (en) 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
PT716697E (pt) 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
KR100392551B1 (ko) 1994-07-15 2003-10-30 아크조 노벨 엔브이 핵산 증폭방법을 개선시키기 위한 rna폴리머라제의 용도
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性dnaを含む組換えイヌアデノウィルス(cav)
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2306457A1 (en) * 1997-10-18 1999-04-29 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
BR0210539A (pt) 2001-06-19 2005-04-26 Us Gov Health & Human Serv Processos de seleção e uso de vacinas de vetor antiartrópode
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU2003287267A1 (en) 2002-10-29 2004-05-25 Centro De Pesquisas Goncalo Moniz Lutzomyia longipalpis polypeptides and methods of use

Also Published As

Publication number Publication date
WO2004027041A3 (en) 2005-02-24
JP2009060912A (ja) 2009-03-26
MXPA05003049A (es) 2005-11-17
JP2006516883A (ja) 2006-07-13
EP1545575A4 (en) 2006-04-05
EP2158917A1 (en) 2010-03-03
US7741437B2 (en) 2010-06-22
AU2003275127A1 (en) 2004-04-08
US20100196381A1 (en) 2010-08-05
WO2004027041A2 (en) 2004-04-01
AU2003275127A8 (en) 2004-04-08
US20060004186A1 (en) 2006-01-05
EP1545575A2 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
BR0200282A (pt) Sistema e método para determinar exigências especìficas a partir de documentos de exigências gerais
ATE440863T1 (de) Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
BR0316564A (pt) Forma de dosagem de alérgeno
IT1214567B (it) Struttura di chiodo endomidollare, ed apparecchiatura per il suo inserimento nell'osso.
HUP0105337A2 (hu) Az immunválaszban szerepet játszó új polipeptidek
BR9707691A (pt) Peptídios antipatogênicos e composições que compreendem os mesmos
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DE69515340D1 (de) Impfstoff gegen mycobakterielle infektionen
DK568287A (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
DE60118359D1 (de) Humanische pellino-polypeptide
BR0314629A (pt) Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso
BR0315872A (pt) Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DE69704807D1 (de) Tragbarer Tauchcomputer
DE59001686D1 (de) Schutzbrille gegen gase.
DK30186A (da) (1,2,4-oxadiazol-3-yl)-arylmethanoner, fremgangsmaade til fremstilling heraf samt deres anvendelse som medikamenter
KR950009817U (ko) 개인용 컴퓨터의 케이스구조
KR950004499U (ko) 휴대용 컴퓨터용 외부 케이스
ATE466076T1 (de) Gewebe transglutaminase
ATE144103T1 (de) Biologischer impfstoff, wirksam gegen aphanomyces
KR940023256U (ko) 개인용 컴퓨터의 전원 확장 장치
BR8604846A (pt) Teclado ergonomico,reduzido e portatil para microcomputadores e assemelhados

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]